Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)

9 Months Ended

Jun. 30, 2016

Schedule of issued note and notes warrants

Subsequent to June 30, 2016, the Company issued multiple Notes and Note Warrants pursuant to the Second Amended Note and Warrant Purchase Agreement to accredited investor of the Company as follows:

Investor	Affiliation	Date		Note Amount		Note Warrant shares issued
John Pappajohn	Director		July 21, 2016	$	250,000		5,000,000
Tierney Family Trust	Greater than 5% shareholder		August 3, 2016		100,000		2,000,000
George and Jill Carpenter	CEO and spouse		August 3, 2016		50,000		1,000,000
RSJ PE	Director Michal Votruba		August 9, 2016		250,000		5,000,000
John Pappajohn	Director		August 9, 2016		100,000		2,000,000
Follman Family Trust	Director		August 10, 2016		100,000		2,000,000
				$	850,000		17,000,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details